The White House confirmed Friday that it plans to install 25% tariffs on goods from Canada and Mexico—effective February ...

The head of the FDA’s artificial intelligence-focused Digital Center of Excellence, Troy Tazbaz, is departing the agency, ...

After spending years developing its endoscopic device treatment for patients with Type 2 diabetes, Fractyl Health is now ...

A sugar produced by soil bacteria may be able to stop the loss of skin pigment caused by vitiligo.  | A sugar produced by ...

During a panel discussion at this year’s Fierce JPM Week—which took place alongside the annual J.P. | This week on “The Top ...

Kadimastem’s attempt to vault onto Nasdaq is picking up momentum, with shareholders signing off on a merger with NLS Pharmaceutics that would enable the cell therapy developer to recover from last ...

Eyeing an expected leap in demand for contrast media—used in X-rays, CT scans and more—GE HealthCare is upping its stake in the Emerald Isle. | GE HealthCare is pumping $138 million into its ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s ...

After leading Japan’s largest drugmaker for 11 years, Takeda CEO Christophe Weber plans to step down in June of 2026. He will ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...